Limits...
p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors.

Yamamoto M, Hosoda M, Nakano K, Jia S, Hatanaka KC, Takakuwa E, Hatanaka Y, Matsuno Y, Yamashita H - Cancer Sci. (2013)

Bottom Line: High p53 expression was positively correlated with tumor grade, HER2 score and Ki-67 expression.Significant association was observed between disease-free survival and high p53 expression in multivariate analysis (P < 0.0001).Compared with women without recurrence, women with early recurrence had significantly higher p53 expression (P < 0.0001), as did women with late recurrence (P = 0.037).

View Article: PubMed Central - PubMed

Affiliation: Breast and Endocrine Surgery, Hokkaido University Hospital, Sapporo, Japan.

Show MeSH

Related in: MedlinePlus

Disease-free survival according to expression of Ki-67 (a), p53 (b) and combination subgroups of Ki-67 and p53 (c) in estrogen-positive breast cancer patients treated with aromatase inhibitors as adjuvant endocrine therapy.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317887&req=5

fig03: Disease-free survival according to expression of Ki-67 (a), p53 (b) and combination subgroups of Ki-67 and p53 (c) in estrogen-positive breast cancer patients treated with aromatase inhibitors as adjuvant endocrine therapy.

Mentions: Univariate analysis demonstrated significant associations between disease-free survival and tumor size, number of positive lymph nodes and expression of Ki-67 and p53 (P < 0.0001, P < 0.0001, P = 0.001, P < 0.0001, respectively; Table4). In the multivariate analysis, significant associations were observed between disease-free survival and high p53 expression (P = 0.001), as well as tumor size (P = 0.001), suggesting that p53 accumulation might be a strong prognostic factor in postmenopausal ER-positive breast cancer patients treated with aromatase inhibitors as adjuvant endocrine therapy. Kaplan–Meier analysis showed that high expression of Ki-67 (≥14%) was significantly associated with decreased disease-free survival (P = 0.0007; Fig.3a). Furthermore, high expression of p53 (≥10%) was strongly and significantly associated with decreased disease-free survival (P < 0.0001; Fig.3b). Combination analysis of expression status for Ki-67 and p53 revealed that patients whose tumors showed both high Ki-67 and high p53 expression had significantly shorter disease-free survival compared with patients whose tumors showed both low Ki-67 and low p53 expression (P < 0.0001; Fig.3c).


p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors.

Yamamoto M, Hosoda M, Nakano K, Jia S, Hatanaka KC, Takakuwa E, Hatanaka Y, Matsuno Y, Yamashita H - Cancer Sci. (2013)

Disease-free survival according to expression of Ki-67 (a), p53 (b) and combination subgroups of Ki-67 and p53 (c) in estrogen-positive breast cancer patients treated with aromatase inhibitors as adjuvant endocrine therapy.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317887&req=5

fig03: Disease-free survival according to expression of Ki-67 (a), p53 (b) and combination subgroups of Ki-67 and p53 (c) in estrogen-positive breast cancer patients treated with aromatase inhibitors as adjuvant endocrine therapy.
Mentions: Univariate analysis demonstrated significant associations between disease-free survival and tumor size, number of positive lymph nodes and expression of Ki-67 and p53 (P < 0.0001, P < 0.0001, P = 0.001, P < 0.0001, respectively; Table4). In the multivariate analysis, significant associations were observed between disease-free survival and high p53 expression (P = 0.001), as well as tumor size (P = 0.001), suggesting that p53 accumulation might be a strong prognostic factor in postmenopausal ER-positive breast cancer patients treated with aromatase inhibitors as adjuvant endocrine therapy. Kaplan–Meier analysis showed that high expression of Ki-67 (≥14%) was significantly associated with decreased disease-free survival (P = 0.0007; Fig.3a). Furthermore, high expression of p53 (≥10%) was strongly and significantly associated with decreased disease-free survival (P < 0.0001; Fig.3b). Combination analysis of expression status for Ki-67 and p53 revealed that patients whose tumors showed both high Ki-67 and high p53 expression had significantly shorter disease-free survival compared with patients whose tumors showed both low Ki-67 and low p53 expression (P < 0.0001; Fig.3c).

Bottom Line: High p53 expression was positively correlated with tumor grade, HER2 score and Ki-67 expression.Significant association was observed between disease-free survival and high p53 expression in multivariate analysis (P < 0.0001).Compared with women without recurrence, women with early recurrence had significantly higher p53 expression (P < 0.0001), as did women with late recurrence (P = 0.037).

View Article: PubMed Central - PubMed

Affiliation: Breast and Endocrine Surgery, Hokkaido University Hospital, Sapporo, Japan.

Show MeSH
Related in: MedlinePlus